Abstract
The pharmacokinetics of epirubicin, an anthracycline, were investigated after intravenous bolus administration (5 mg/kg) in mice, rats, rabbits and dogs. Based on animal data, we predicted the following human pharmacokinetic parameters using allometric scaling: 120 and 35.2 L/h for total body clearance (CLt) using simple and maximum life-span potential (MLP)-corrected allometry, respectively; 702 L for steady-state volume of distribution (Vdss). The scaled Vdss value was twofold lower than the corresponding values in humans. However, the scaled CLt values were consistent with those clinically observed in humans (35.6–133.4 L/h). We also predicted human parameters using species-invariant time transformations (equivalent time, kallynochrons, apolysichrons and dienetichrons). The mean Vdss (854 L) obtained using kallynochrons and that derived from simple allometry were comparable. The lowest CLt (121 L/h) derived using kallynochrons was comparable to that obtained using simple allometry. The results of this study also indicated that the predicted human CLt generated using MLP-corrected allometry can be used for the selection of a safe dose for studies in healthy adult human volunteers. These results suggest that such approaches may be useful in designing pharmacokinetic studies for novel anthracyclines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bertazzoli C, Rovero C, Ballerini L, Lux B, Balconi F, Antongiovanni V, Magrini U (1985) Experimental systemic toxicology of 4′-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol Appl Pharmacol 79:412–422
Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharm 10:201–227
Boxenbaum H (1984) Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev 15:1071–1121
Boxenbaum H, Ronfeld R (1983) Interspecies pharmacokinetic scaling and the Dedrick plots. Am J Physiol 245:768–775
Camaggi CM, Comparsi R, Strocchi E, Testoni F, Angelelli B, Pannuti F (1988) Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study. Cancer Chemother Pharmacol 21:221–228
Camaggi CM, Strocchi E, Carisi P, Martoni A, Melotti B, Pannuti F (1993) Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study. Cancer Chemother Pharmacol 32:301–309
Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093–1095
Dedrick R, Bischoff KB, Zaharko DS (1970) Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 54:95–101
Ganzina F (1983) 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10:1–22
Hu OY, Chang SP, Jame JM, Chen KY (1989) Pharmacokinetic and pharmacodynamic studies with 4′-epi-doxorubicin in nasopharyngeal carcinoma patients. Cancer Chemother Pharmacol 24:332–337
Kimura K, Wakui A, Saito T, Tominaga T, Niitani H, Fujimoto T, Masaoka T, Toki H, Tamura K (1984) A phase I study of 4′-epi-adriamycin, a new anthracycline anticancer agent. Gan To Kagaku Ryoho 11:2414–2419
Lee HS, Ryu JS, Jeon YJ, Hong YS, Lee JJ, Hong SK, Kim TY (2007) Apoptosis induced by ID6105, a new anthracycline (11-hydroxyaclacinomycin X, Hyrubicin), and its anti-tumor effects on experimental tumor models. Cancer Chemother Pharmacol 60:197–201
Mahmood I (2007) Application of allometric principles for the prediction of pharmacokinetics in human and veterinary drug development. Adv Drug Deliv Rev 59:1177–1192
Mahmood I, Balian JD (1996) Interspecies scaling: a comparative study for the prediction of clearance and volume using two of more than two species. Life Sci 59:579–585
Reigner BG, Blesch KS (2002) Estimating the starting dose for entry into humans: principles and practice. Eur J Clin Pharmacol 57:835–845
Robert J (1994) Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26:428–438
Robert J, Bui NB (1992) Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. Ann Oncol 3:651–656
Robert J, Gianni L (1993) Pharmacokinetics and metabolism of anthracyclines. Cancer Surv 17:219–252
Ryu JS, Lee HS, Hong YS, Lee JJ, Sohn UD, Kim TY (2006) In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin). Cancer Chemother Pharmacol 57:811–818
Sawyer M, Ratain MJ (2001) Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs 19:171–177
Shin BS, Kim DH, Cho CY, Park SK, Chung SG, Cho EH, Lee SH, Joo JH, Kwon HS, Lee KC, Yoo SD (2003) Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, by species-invariant time methods. Biopharm Drug Dispos 24:191–197
Shin DH, Choi KS, Park SA, Cho BS, Lee HS, Ryu JS, Kim TY, Lee CK, Song S, Chung YB (2008) Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells. Arch Pharm Res 31:1355–1361
Shin DH, Park SH, Jeong SW, Park CW, Han K, Chung YB (2013) Validation of HPLC method to determine epirubicin and its pharmacokinetics after i.v. bolus administration in rats. J Pharm Invest 43:243–249
Shin DH, Park SH, Jeong SW, Park CW, Han K, Chung YB (2014) Hepatic uptake of epirubicin by isolated rat hepatocytes and its biliary excretion after intravenous infusion in rats. Arch Pharm Res 37:1599–1606
Snyder R, Bishop J, Brodie G, Burns W, Coates A, Levi J, Raghavan D, Schwarz M, Tattersall M, Thomson D (1987) Phase I study of epirubicin given on a weekly schedule. Cancer Treat Rep 71:273–276
Von Hoff DD, Rozencweig M, Piccart M (1982) The cardiotoxicity of anticancer agents. Semin Oncol 9:23–33
Yamaoka K, Tanigawara Y, Nakagawa T, Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4:879–885
Yoo BI, Ahan KB, Kang MH, Kwon OS, Hong YS, Lee JJ, Lee HS, Ryu JS, Kim TY, Moon DC, Song S, Chung YB (2005a) Pharmacokinetics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, after i.v. bolus multiple administration in rats. Arch Pharm Res 28:476–482
Yoo BI, Ahan KB, Kang MH, Moon DC, Kwon OS, Lee HS, Ryu JS, Kim TY, Song S, Chung YB (2005b) HPLC analysis and pharmacokinetic characteristics of 11-hydroxyaclacinomycin X (ID-6105), a novel anthracycline, in rats and beagle dogs. Biol Pharm Bull 28:688–693
Acknowledgments
This work was supported by a research grant from Chungbuk National University in 2012. All authors (Shin DH, Park SH, Jeong SW, Kwon O-S, Park C-W, Han K and Chung YB) declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Shin, D.H., Park, S.H., Jeong, S.W. et al. Pharmacokinetic scaling of epirubicin using allometric and species-invariant time methods. Journal of Pharmaceutical Investigation 45, 441–448 (2015). https://doi.org/10.1007/s40005-015-0189-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-015-0189-9